RxDoctor Payments Data

William Young, MD

Urology · Crossville, TNNPI 1952308421

Payments from drug & device makers

$8,151in general payments, 2019–2025

Across 322 payments — averaging $25.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • Astellas Pharma US Inc$799
  • AbbVie$735
  • Boston Scientific$484
  • Sumitomo Pharma America, Inc.$457
  • Medtronic$354
  • plus $4K from 47 others

What the payments were for

  • Speaking & faculty fees$4506%
  • Travel & lodging$1,30816%
  • Food & beverage$6,24977%
  • Education$1442%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,151 in reported general payments places this provider in the 65th percentile of 276 urology providers in Tennessee.

See all urology providers in Tennessee

Medicare billing

Part B allowed, 2024
$261,997
Medicare patients
787
Services billed
21,765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron117$83,841
MyrbetriqMirabegron97$76,944
Tamsulosin Hcl951$19,652
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst260$13,583
Trimethoprim84$5,908
Alfuzosin Hcl ErAlfuzosin Hcl280$4,941
Testosterone32$4,493
Finasteride266$3,993
Solifenacin Succinate32$3,383
Oxybutynin Chloride146$3,051
Silodosin17$2,764
Bethanechol Chloride31$2,118
Sildenafil Citrate42$2,105
Estradiol25$1,747
Potassium Citrate ErPotassium Citrate17$1,628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$457$83,841117 claims
Astellas Pharma US IncMyrbetriq$799$76,94497 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 276 urology providers in Tennessee.

Other urology in Crossville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →